Douglas A. Rubinson

7.6k total citations · 1 hit paper
47 papers, 3.3k citations indexed

About

Douglas A. Rubinson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Douglas A. Rubinson has authored 47 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Douglas A. Rubinson's work include Pancreatic and Hepatic Oncology Research (21 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cellular Mechanics and Interactions (6 papers). Douglas A. Rubinson is often cited by papers focused on Pancreatic and Hepatic Oncology Research (21 papers), Colorectal Cancer Treatments and Studies (7 papers) and Cellular Mechanics and Interactions (6 papers). Douglas A. Rubinson collaborates with scholars based in United States, Germany and United Kingdom. Douglas A. Rubinson's co-authors include Frank B. Gertler, Adam V. Kwiatkowski, Christopher P. Dillon, Luk Van Parijs, Claudia Sievers, Martin Scott, Mingdi Zhang, Johnny E. Kopinja, Michael T. McManus and Lili Yang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neuron and Nature Genetics.

In The Last Decade

Douglas A. Rubinson

43 papers receiving 3.3k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference

2003 1.3k citations Douglas A. Rubinson, Adam V. Kwiatkowski et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas A. Rubinson United States	22	1.9k	831	759	470	423	47	3.3k
Joseph L. Kissil United States	35	2.7k 1.4×	1.2k 1.5×	1.2k 1.6×	610 1.3×	234 0.6×	59	4.4k
Yoshiki Murakumo Japan	38	3.3k 1.8×	1.1k 1.3×	560 0.7×	849 1.8×	432 1.0×	129	4.7k
Ma. Xenia G. Ilagan United States	18	3.2k 1.7×	579 0.7×	477 0.6×	477 1.0×	397 0.9×	27	4.3k
Masayuki Komada Japan	37	3.0k 1.6×	750 0.9×	1.3k 1.7×	346 0.7×	346 0.8×	80	4.8k
Letizia Lanzetti Italy	26	2.2k 1.1×	658 0.8×	1.4k 1.9×	443 0.9×	176 0.4×	39	3.6k
Timothy M. Thomson Spain	32	2.6k 1.4×	916 1.1×	587 0.8×	503 1.1×	281 0.7×	81	3.8k
Dianqing Wu United States	40	3.7k 2.0×	616 0.7×	880 1.2×	386 0.8×	576 1.4×	85	5.3k
Ruth H. Palmer Sweden	41	3.1k 1.6×	1.3k 1.6×	899 1.2×	728 1.5×	312 0.7×	121	5.4k
Per Hydbring Sweden	20	3.6k 1.9×	1.5k 1.8×	754 1.0×	708 1.5×	232 0.5×	38	5.0k
Sue-Hwa Lin United States	43	2.8k 1.5×	1.7k 2.1×	615 0.8×	615 1.3×	376 0.9×	136	5.1k

Countries citing papers authored by Douglas A. Rubinson

Since Specialization

Citations

This map shows the geographic impact of Douglas A. Rubinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas A. Rubinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas A. Rubinson more than expected).

Fields of papers citing papers by Douglas A. Rubinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas A. Rubinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas A. Rubinson. The network helps show where Douglas A. Rubinson may publish in the future.

Co-authorship network of co-authors of Douglas A. Rubinson

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas A. Rubinson. A scholar is included among the top collaborators of Douglas A. Rubinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas A. Rubinson. Douglas A. Rubinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Perez, Kimberly, Matthew H. Kulke, Hui Zheng, et al.. (2025). A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors. The Oncologist. 30(1).

Rubinson, Douglas A., Noritaka Tanaka, Ferran Fece de la Cruz, et al.. (2024). Sotorasib Is a Pan- RAS G12C Inhibitor Capable of Driving Clinical Response in NRAS G12C Cancers. Cancer Discovery. 14(5). 727–736. 23 indexed citations

Barzi, Afsaneh, Howard West, David T. Wong, et al.. (2023). Pancreatic Adenocarcinoma: Real World Evidence of Care Delivery in AccessHope Data. Journal of Personalized Medicine. 13(9). 1377–1377. 1 indexed citations

Kang, Yu Mi, Douglas A. Rubinson, Igor Odintsov, et al.. (2023). FRI610 Phosphatidylinositol 3-kinase Inhibition With Alpelisib Is Safe And Effective In Treating Refractory Hypoglycemia Associated With Malignant Insulinoma. Journal of the Endocrine Society. 7(Supplement_1).

Huffman, Brandon M., Haley Ellis, Alexander C. Jordan, et al.. (2022). Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Cancers. 14(24). 6223–6223. 14 indexed citations

Khayat-Khoei, Mahsa, et al.. (2021). Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab. Journal of Neurology. 268(10). 3592–3594. 10 indexed citations

Rubinson, Douglas A., Brian M. Wolpin, Ilana S. Warsofsky, et al.. (2021). Durable clinical benefit from PARP inhibition in a platinum-sensitive, BRCA2-mutated pancreatic cancer patient after earlier progression on placebo treatment on the POLO trial: a case report. Journal of Gastrointestinal Oncology. 12(6). 3133–3140. 4 indexed citations

Hamada, Tsuyoshi, Chen Yuan, Matthew B. Yurgelun, et al.. (2019). Family history of cancer, Ashkenazi Jewish ancestry, and pancreatic cancer risk. British Journal of Cancer. 120(8). 848–854. 15 indexed citations

Hamada, Tsuyoshi, Natalia Khalaf, Chen Yuan, et al.. (2018). Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology. 16(8). 1300–1306.e3. 20 indexed citations

10.

Yurgelun, Matthew B., Anu Chittenden, Chinedu Ukaegbu, et al.. (2018). Implementing universal genetic counseling (GC) and multigene germline testing (MGT) for pancreatic cancer (PC) patients (pts).. Journal of Clinical Oncology. 36(15_suppl). 1512–1512. 3 indexed citations

11.

Babić, Ana, Nader Rifai, Marisa W. Welch, et al.. (2018). Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clinical and Translational Gastroenterology. 9(4). e145–e145. 36 indexed citations

12.

Yuan, Chen, Zhi Rong Qian, Ana Babić, et al.. (2016). Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. Journal of Clinical Oncology. 34(24). 2899–2905. 37 indexed citations

13.

Rubinson, Douglas A. & Brian M. Wolpin. (2015). Therapeutic Approaches for Metastatic Pancreatic Adenocarcinoma. Hematology/Oncology Clinics of North America. 29(4). 761–776. 11 indexed citations

14.

Wolpin, Brian M., Douglas A. Rubinson, Xiaoxu Wang, et al.. (2014). Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma. The Oncologist. 19(6). 637–638. 289 indexed citations

15.

Furman, Craig, Alisha L. Sieminski, Adam V. Kwiatkowski, et al.. (2007). Ena/VASP is required for endothelial barrier function in vivo. The Journal of Cell Biology. 179(4). 761–775. 93 indexed citations

16.

Kwiatkowski, Adam V., Douglas A. Rubinson, Erik W. Dent, et al.. (2007). Ena/VASP Is Required for Neuritogenesis in the Developing Cortex. Neuron. 56(3). 441–455. 169 indexed citations

17.

Krause, Matthias, Jonathan D. Leslie, Mary Q. Stewart, et al.. (2004). Lamellipodin, an Ena/VASP Ligand, Is Implicated in the Regulation of Lamellipodial Dynamics. Developmental Cell. 7(4). 571–583. 259 indexed citations

18.

Tsai, Kenneth Y., David MacPherson, Douglas A. Rubinson, et al.. (2002). ARF mutation accelerates pituitary tumor development in Rb +/− mice. Proceedings of the National Academy of Sciences. 99(26). 16865–16870. 35 indexed citations

19.

Loureiro, Joseph, Douglas A. Rubinson, James E. Bear, et al.. (2002). Critical Roles of Phosphorylation and Actin Binding Motifs, but Not the Central Proline-rich Region, for Ena/Vasodilator-stimulated Phosphoprotein (VASP) Function during Cell Migration. Molecular Biology of the Cell. 13(7). 2533–2546. 115 indexed citations

20.

Tsai, Kenneth Y., David MacPherson, Douglas A. Rubinson, Denise Crowley, & Tyler Jacks. (2002). ARF Is Not Required for Apoptosis in Rb Mutant Mouse Embryos. Current Biology. 12(2). 159–163. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact